Drug Profile

STC 004

Alternative Names: STC-004

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stanford University
Developer SiteOne Therapeutics
Class Analgesics; Small molecules
Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Pain

Most Recent Events

04 Feb 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Pain released by SiteOne Therapeutics
04 Feb 2025 SiteOne Therapeutics plans a phase II trial for Pain, in the second half of the year 2025 (PO)
03 Dec 2024 SiteOne Therapeutics completes a phase I trial (In volunteers) in Pain in New Zealnad (ACTRN12624000642583, STC-004-CS-001)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com